• FirefoxUpgrade to the new Firefox »
  •  Dow Up1.31% Nasdaq Up0.98%

    Alkermes plc (ALKS)

    -NasdaqGS
    72.19 Up 0.79(1.11%) 4:00PM EST
    |After Hours : 72.19 0.00 (0.00%) 4:15PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Alkermes plc
    Connaught House
    1 Burlington Road
    Dublin, 4
    Ireland - Map
    Phone: 353 1 772 8000
    Website: http://www.alkermes.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Delivery
    Full Time Employees:1,250

    Business Summary 

    Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for moderate to severe pain; EMEND to treat nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES to treat cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE to prevent renal transplant rejection; NAPRELAN for mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFEDlTAB CR for hypertension; DILZEM SR, DILZEM XL, DILTELAN, and CARDIZEM CD for hypertension and/or angina; and ZOHYDRO ER for severe pain. In addition, it is developing Aripiprazole Lauroxil for the treatment of schizophrenia; ALKS 33, which has completed Phase II study for modulation of brain opioid receptors; ALKS 5461 that is under Phase III study for the treatment of depressive disorder; ALKS 3831, a phase II study medicine to treat schizophrenia; ALKS 8700, a prodrug of monomethyl fumarate to treat multiple sclerosis; ALKS 7106, a small-molecule product candidate to treat pain with intrinsically low potential for abuse and overdose death; and RDB 1419, a proprietary biologic cancer immunotherapy candidate. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration agreements with Janssen Pharmaceutica, NV; AstraZeneca plc; Acorda Therapeutics, Inc.; and other collaboration partners. The company was founded in 1987 and is headquartered in Dublin, Ireland.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Alkermes plc

    Corporate Governance 
    Alkermes plc’s ISS Governance QuickScore as of Jan 1, 2015 is 5. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 4; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Richard F. Pops , 53
    Chairman and Chief Exec. Officer
    2.42M6.00M
    Mr. Shane Cooke , 53
    Pres
    1.50M0.00
    Dr. Floyd E. Bloom M.D., 78
    Co-Founder, Director and Member of Audit & Risk Committee
    66.00KN/A
    Mr. James M. Frates , 48
    Chief Financial Officer, Principal Accounting Officer, Sr. VP and Treasurer
    776.00K3.56M
    Ms. Kathryn L. Biberstein , 56
    Chief Legal Officer, Chief Compliance Officer, Sr. VP of Gov. Relations & Public Policy and Sec.
    848.00K1.04M
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders